NRX Pharmaceuticals, Inc.
As of Oct 22, 2026, NRX Pharmaceuticals is in Stage 3, the topping phase, now in week 10 (since Aug 17, 2026). It closed at $2.40, 48.1% below its 52-week high and below its 200-day average, which is rising.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NRXP early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NRXP among Biotechnology265th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …265 | NRXP | Stage 3 · wk 10 | 36 | −24.1% |
NRX Pharmaceuticals: quick answers
What stage is NRX Pharmaceuticals in?
As of Oct 22, 2026, NRX Pharmaceuticals (NRXP) is in Stage 3, the topping phase. It entered Stage 3 on Aug 17, 2026 and is in week 10. What the four stages mean
Is NRX Pharmaceuticals in an uptrend?
Its uptrend has stalled. NRX Pharmaceuticals is in Stage 3, the topping phase that follows an advance. It trades 18.9% below its 200-day average, which is rising.
How far is NRX Pharmaceuticals from its 52-week high?
NRX Pharmaceuticals closed at $2.40 on Oct 22, 2026, 48.1% below its 52-week high of $4.62. Its 52-week low is $1.68.
How has NRX Pharmaceuticals performed over the past year?
As of Oct 22, 2026, NRX Pharmaceuticals is down 25.2% over the past year and down 8.4% so far in 2026.
Which sector and industry is NRX Pharmaceuticals in?
NRX Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.